<>
CD19 CAR T cell therapy for treatment-refractory seropositive rheumatoid arthritis showed clinical safety and efficacy in a phase 1 trial published in Nature Medicine on August 27, 2026. Evaluating mivocabtagene autoleucel in the COMPARE trial, researchers found that the treatment reduced disease activity and depleted autoantibodies without unexpected toxicities.
For patients suffering from severe autoimmune conditions that resist standard medical management, this milestone offers a radically different therapeutic paradigm. Traditional treatment relies on lifelong, broad immunosuppression to dampen symptoms rather than resetting the immune system. By targeting the underlying cellular drivers of disease, this approach aims for true, drug-free remission.
In Plain English: The Clinical Takeaway
- Immune Reset: The therapy uses genetically engineered immune cells to clear out the specific white blood cells producing damaging autoantibodies.
- Treatment-Free Remission: Several trial participants maintained clinical improvement even after stopping standard immunosuppressive drugs.
- Manageable Side Effects: Observed complications like cytokine release syndrome were mild to moderate, with no severe neurotoxicity reported.
Phase 1 Data and the Cellular Mechanism of Action
Rather than rebuilding immune tolerance, standard rheumatoid arthritis treatments depend on continuous immunosuppression, making lasting remissions off medication uncommon. Recent case observations indicate that CD19-targeted chimeric antigen receptor T (CAR-T) cell therapy could prove to be an effective strategy. Fredrik Albach shared findings on mivocabtagene autoleucel—an autologous, completely human CD19-targeted CAR-T cell therapy—at the 2026 Congress of EULAR – The European Alliance of Associations for Rheumatology, highlighting phase 1 data from the open-label, prospective COMPARE trial involving six individuals with active, treatment-refractory rheumatoid arthritis who tested positive for anti-citrullinated protein antibodies (ACPA).
The mechanism of action centers on engineering a patient’s own T cells to target CD19-expressing B cells. Overall, the therapy was well tolerated; cytokine release syndrome (CRS) events remained mild to moderate, and investigators noted zero instances of immune effector cell-associated neurotoxicity syndrome (ICANS) or unexpected adverse effects. CAR-T cells expanded rapidly and peaked within three weeks, followed by a gradual decline, effectively depleting B cells in both blood and tissues. Participants demonstrated a substantial drop in autoantibodies, reflecting a median decrease exceeding 90%, alongside durable seroconversion to normal ACPA levels in four individuals and for RF-IgM in five.
All participants also recorded a decrease in disease activity, marked by a median 49% DAS28-CRP reduction. ACR20, ACR50, and ACR70 responses occurred in 5 out of 6, 4 out of 6, and 2 out of 6 patients respectively, while half achieved sustained remission in the absence of ongoing immunosuppressive therapy. B cell repopulation did not result in the reappearance of ACPA-positive memory B cells, a rise in autoantibodies, or increased disease activity. With the exception of one patient who needed to revert to glucocorticoid therapy due to a moderate flare on withdrawal, all participants remained off immunosuppressive drugs at the time of data cut-off, with a follow-up window of 24 to 36 weeks.
Broadening the Autoimmune Landscape: Systemic Sclerosis and Beyond
Beyond rheumatoid arthritis, researchers are testing similar cellular reset strategies in other refractory autoimmune diseases. Another group reported on the first multicenter experience of dual-target CAR-T using CD19 and BCMA in 11 patients suffering from refractory systemic sclerosis. All patients achieved rapid B-cell aplasia. Skin thickness scores improved significantly from baseline, with 73% reaching low disease activity. Functional disability, measured by the HAQ-DI score, dropped from 1.0 to 0.2, while both physician and patient global assessments fell.
Yajing Zhang from Beijing GoBroad Boren Hospital in China addressed the broader implications of these findings during data presentations, stating, Dual-target CD19/BCMA CAR-T cell therapy induces profound and sustained clinical remission in refractory systemic sclerosis. By effectively targeting both skin fibrosis and lung progression, this immunological ‘reset’ strategy offers true curative potential, paving the way for Phase 2 trials to redefine the future management of this severe disease.
Treatment also addressed lung progression in systemic sclerosis patients, showing stabilization or improvement in lung volume and oxygen transfer. High-resolution computed tomography scans confirmed the regression of interstitial changes in 80% of patients with baseline interstitial lung disease, and no disease flares occurred during follow-up. Furthermore, Yuichi Maeda and colleagues investigated the gut microbiome and fecal IgA effects in patients with severe systemic lupus erythematosus, systemic sclerosis, or idiopathic inflammatory myopathy who received zorpocabtagene autoleucel. Their analysis showed that overgrowth of specific bacterial species decreased following the cellular intervention.
| Metric | Observed Trial Result |
|---|---|
| Patient Cohort Size | 6 patients (ACPA-positive, treatment-refractory) |
| Autoantibody Reduction | Median reduction >90% |
| Disease Activity | Median 49% DAS28-CRP reduction |
| Adverse Events | Mild-to-moderate CRS; zero ICANS |
References
- Nature Medicine: CD19 CAR T cell therapy for treatment-refractory seropositive rheumatoid arthritis: a phase 1 trial (Published: 27 August 2026). DOI: 10.1038/s41591-026-04603-3
- European Alliance of Associations for Rheumatology (EULAR): Annual Congress Abstracts and Presentations (June 2026).
This reporting does not constitute formal medical diagnosis, treatment planning, or professional healthcare advice. Always consult a qualified rheumatologist or specialist regarding autoimmune disease management.
